• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Varian stands on $1.28B offer for Sirtex

May 22, 2018 By Sarah Faulkner

Varian to acquire SirtexVarian Medical (NYSE:VAR) said today that it stands behind its initial $1.28 billion bid to acquire Sirtex Medical (ASX:SRX) in the wake of a $1.41 billion counter offer from China’s CDH Investments.

The unsolicited bid from CDH Investments came in at a 20% premium on Varian’s A$28-per-share offer, prompting Sirtex to reconsider a merger that already has approval from U.S. antitrust authorities and the German Federal Cartel Office.

Varian formally notified Sirtex that it does not plan to submit a counter proposal.

“The board of directors of Sirtex is considering the relative merits and risks of the CDH Proposal compared to the Varian Scheme, including the respective offer prices, the risks and timing to completion and the potential outcomes for Sirtex shareholders if a control transaction does not complete.  The board of directors of Sirtex has not yet formed a view on these matters and continues to unanimously support and recommend the Varian Scheme,” Varian said in a statement.

Sirtex faced an array of obstacles last year, including clinical trials of its resin microsphere that failed to meet primary endpoints.

Australia-based Sirtex’s SIR-Sphere Y-90 is designed to deliver radiation therapy to patients with liver cancers. Last year, shares in the company developer fell sharply after it posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before.

A “general uptick in competition for patients with liver-directed therapies and a generally tighter reimbursement environment” was partly to blame for what CEO Andrew McLean described as a “challenging” year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: CDH Investments, Sirtex Medical, Varian Medical Systems

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS